Date Title Format

18/12/2001

Share Issue

HTML Page

06/12/2001

Further fundraising

HTML Page

19/11/2001

ReGen strengthen it’s Colostrinin™ IP rights

HTML Page

06/11/2001

Directors shareholdings

HTML Page

05/11/2001

Placing of ordinary shares

HTML Page

30/10/2001

ReGen to acquire full ownership of its Colostrinin™ IP rights

HTML Page

26/10/2001

Trial recruitment complete

HTML Page

17/10/2001

Update on placing of ordinary shares

HTML Page

11/10/2001

Placing of Ordinary Shares

HTML Page

28/09/2001

Interim Results announcement for the six months ended 30 June 2001

PDF

16/07/2001

Shares in Issue: 52.54m 5p Ordinary shares

HTML Page

11/04/2001

Colostrinin™ Clinical Trial – Interim Data Assessment

HTML Page

07/04/2001

Board Change

HTML Page

19/02/2001

Michael Harvey appointed Chief Executive Officer of ReGen Therapeutics Plc

HTML Page
Get Adobe Reader If you are unable to view the PDF documents you may need to download the free Adobe Reader